The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
{\displaystyle \mathbf {V} (f_{n},\tau _{n})={\begin{bmatrix}cosh(\tau _{n}{\sqrt {-f_{n})}}&1/{\sqrt {-f_{n}}}sinh(\tau _{n}{\sqrt {-f_{n}}}\\{\sqrt {-f_{n}}}sinh(\tau _{n}{\sqrt {-f_{n}}})&cosh(\tau _{n}{\sqrt {-f_{n}}})\end{bmatrix}}\qquad f_{n}<0\qquad \qquad (3b)}
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
Half Life is the 2006 debut novel of American writer and artist Shelley Jackson. The novel presupposes an alternate history in which the atomic bomb resulted in a genetic preponderance of conjoined twins, who eventually become a minority subculture.
Sources: en.wikipedia.org
==== Rapid expansion ==== By the end of 1858 there were already eight firms producing aniline dyes. By 1861 there were twenty-nine British patents on coloring matters from aniline. By 1864 68 firms were producing dyes. This was driven by the textile industry, which employed new designs requiring the colorful aniline dyes. Even Hofmann, who had at first criticized his student for leaving his academic research of quinine, later synthesized his own aniline dye, rosaniline. In 1858 the German chemist Johann Peter Griess obtained a yellow dye by reacting nitrous acid with aniline. It didn't last commercially, but it created even more interest in aniline as precursor for colorful compounds. French chemist François-Emmanuel Verguin reacted aniline with stannic chloride to yield fuchsine, a rose colored dye, the first of the triphenylmethane dyes. Further work by Hoffman along with the discovery of benzene’s structure (1858) and carbon’s tetravalency(1865), this science built the groundwork for modern organic chemistry. In the late 1860s many companies began offering a full spectrum of colors, and were already outcompeting many natural dyes for market share. Prices continually fell, and new colors and products regularly entered the market. On January 1, 1868, there were 52 producers of aniline dyes. Members of enlightened scientific societies from all over Europe including the Manchester Literary & Philosophical Society competed for expertise and authority with dyers and printers in factories and workshops.
For years Kracauer read [Kant's] Critique of Pure Reason with me regularly on Saturday afternoons. I am not exaggerating in the slightest when I say that I owe more to this reading than to my academic teachers ... Under his guidance, I experienced the work from the beginning not as mere epistemology, not as an analysis of the conditions of scientifically valid judgments, but as a kind of coded text from which the historical situation of spirit could be read, with the vague expectation that in doing so one could acquire something of truth itself. Leaving grammar school to study philosophy, psychology and sociology at Johann Wolfgang Goethe University in Frankfurt, Adorno continued his readings with Kracauer, turning now to Hegel and Kierkegaard, and began publishing concert reviews and pieces of music for distinguished journals like the Zeitschrift für Musik, the Neue Blätter für Kunst und Literatur and later for the Musikblätter des Anbruch. In these articles, Adorno championed avant-garde music at the same time as he critiqued the failings of musical modernity, as in the case of Stravinsky's The Soldier's Tale, which in 1923 he called a "dismal Bohemian prank." In these early writings, he was unequivocal in his condemnation of performances that either sought or pretended to achieve a transcendence that Adorno, in line with many intellectuals of the time, regarded as impossible.
While modern identification of mushrooms is quickly becoming molecular, the standard methods for identification are still used by most and have developed into a fine art harking back to medieval times and the Victorian era, combined with microscopic examination. The presence of juices upon breaking, bruising-reactions, odors, tastes, shades of color, habitat, habit, and season are all considered by both amateur and professional mycologists. Tasting and smelling mushrooms carries its own hazards because of poisons and allergens. Chemical tests are also used for some genera. In general, identification to genus can often be accomplished in the field using a local field guide. Identification to species, however, requires more effort. A mushroom develops from a button stage into a mature structure, and only the latter can provide certain characteristics needed for the identification of the species. However, over-mature specimens lose features and cease producing spores. Many novices have mistaken humid water marks on paper for white spore prints, or discolored paper from oozing liquids on lamella edges for colored spored prints.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.